↓ Skip to main content

Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway

Overview of attention for article published in Stem Cell Research & Therapy, June 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway
Published in
Stem Cell Research & Therapy, June 2022
DOI 10.1186/s13287-022-02888-y
Pubmed ID
Authors

Tomoka Takao, Hirotaka Masuda, Takashi Kajitani, Fumie Miki, Kaoru Miyazaki, Yushi Yoshimasa, Satomi Katakura, Shoko Tomisato, Sayaka Uchida, Hiroshi Uchida, Mamoru Tanaka, Tetsuo Maruyama

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 40%
Professor > Associate Professor 1 20%
Unknown 2 40%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 20%
Agricultural and Biological Sciences 1 20%
Immunology and Microbiology 1 20%
Medicine and Dentistry 1 20%
Unknown 1 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2022.
All research outputs
#20,712,517
of 23,312,088 outputs
Outputs from Stem Cell Research & Therapy
#2,093
of 2,453 outputs
Outputs of similar age
#359,386
of 445,189 outputs
Outputs of similar age from Stem Cell Research & Therapy
#86
of 107 outputs
Altmetric has tracked 23,312,088 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,453 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,189 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 107 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.